Cantargia – executive interview

Cantargia – executive interview

Associated equity: Cantargia

Cantargia is a clinical-stage biotechnology company based in Sweden. It is developing two assets against IL1RAP, CAN04 and CAN10. CAN04 is being studied in several solid tumours with a main focus on non-small cell lung cancer (NSCLC) and pancreatic cancer. The most advanced trial is in Phase II.

Cantargia — 8 videos in collection

Cantargia is a clinical-stage biotechnology company based in Sweden, established in 2009 and listed on the Nasdaq Stockholm main market. Its lead asset nadunolimab (CAN04) is being investigated as a treatment for several types of solid tumours across a broad programme; the most advanced indications are pancreatic cancer and non-small cell lung cancer. CAN10, the second lead asset, is being developed for systemic sclerosis and myocarditis, with clinical development expected to start in 2022. In this video, the company’s chief executive officer Göran Forsberg provides an update on R&D progress and the upcoming newsflow.

You may also be interested in these:


Cantargia - executive interview


Cantargia: Edison Open House Healthcare 2022

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free